Hansa Biopharma interim report Jan-June 2021
Idefirix[®] recommended by Swedish New Therapies Council for use in highly sensitized kidney patients in Sweden. U.S. trial design announced; first patient expected to be dosed H2 2021Lund, Sweden July 15, 2021 Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January – June, 2021. Highlights for the second quarter 2021 · Commercial launch activities for Idefirix[®] in Europe are progressing as planned in early launch countries, such as the Nordics, Benelux, U.K. and Germany.